Anixa Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amit Kumar
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3150 Almaden Expressway San Jose CA United States of America 95118
- IPO Date
- Oct 7, 1983
- CIK
- 0000715446
- Website
- anixa.com
- Similar Companies
- Business
- Anixa Biosciences Inc (NASDAQ:ANIX) operates as a clinical-stage biotechnology company focused on developing therapies and vaccines for cancer treatment and prevention. The company offers a therapeutics portfolio featuring chimeric endocrine receptor T-cell (CER-T) immunotherapy, including liraltagene autoleucel (lira-cel), an FSHR-targeted CAR-T therapy exclusively licensed from The Wistar Institute for recurrent ovarian cancer, conducted in Phase 1 trials with Moffitt Cancer Center; its vaccine portfolio, developed with Cleveland Clinic, targets retired proteins in triple negative breast cancer (TNBC), ovarian cancer, and additional programs for lung, colon, and prostate cancers. Founded in 1982 and headquartered in San Jose, California, Anixa conducts operations primarily in the United States through collaborations with leading research institutions. Recent developments include World Health Organization approval in November 2025 of the international non-proprietary name liraltagene autoleucel for its CAR-T therapy, marking a milestone toward commercialization; expansion in May 2024 of its Cleveland Clinic partnership for novel cancer vaccines; a $5 million share repurchase program authorized in July 2024; and a letter of intent with VERDI Solutions for artificial intelligence applications in development.
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Reviewing AVAX Technologies (OTCMKTS:AVXT) & Anixa Biosciences (NASDAQ:ANIX)
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress